06Mar 2024
Strides Pharma Gains USFDA Approval for Gabapentin Tablets USP

Strides Pharma Gains USFDA Approval for Gabapentin Tablets USP

Strides Pharma Global Pte. Limited, secures USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg. The medication, used for partial seizures and neuropathic pain, is bioequivalent to Neurontin Tablets. With a market size of US$140Mn, this approval strengthens the company's Gabapentin portfolio, complementing existing capsule approvals.

  • #family health

Like

Save

Share